Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest adenosine Stories

2010-03-14 14:31:51

The drug regadenoson is safe and poses fewer side effects than the conventional medication used during a cardiac nuclear stress test of heart transplant patients, according to a Henry Ford Hospital study. Researchers say the 25 patients in the study did not experience adverse side effects such as abnormally low blood pressure or slow heart beat when regadenoson was used during the stress test. Additionally, patients showed no signs of heart block, a condition in which the signal from the...

236bb0bb50b3146a7f4f551f3a79ca9e
2010-03-03 09:13:13

While it is not proven that coffee is protective, it is unlikely that moderate caffeine intake increases arrhythmia risk, Kaiser Permanente study finds SAN FRANCISCO -- Coffee drinkers may be less likely to be hospitalized for heart rhythm disturbances, according to a new study by the Kaiser Permanente Division of Research in Oakland, Calif. The researchers, who note the findings may be surprising because patients frequently report palpitations after drinking coffee, are presenting the study...

2010-03-02 17:00:00

SAN FRANCISCO, March 2 /PRNewswire/ -- Coffee drinkers may be less likely to be hospitalized for heart rhythm disturbances, according to a new study by the Kaiser Permanente Division of Research in Oakland, Calif. The researchers, who note the findings may be surprising because patients frequently report palpitations after drinking coffee, are presenting the study at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in San...

2010-02-25 09:00:00

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018 in the acute coronary syndrome drug market, the overall uptake of Eli Lilly/Daiichi Sankyo's Effient in the United States and Europe (where it is marketed as Efient) will be constrained by the widespread use of AstraZeneca's Brilinta, which is expected to launch in 2011. The Pharmacor 2010 findings from the...

2010-01-26 08:00:00

WORCESTER, Mass., Jan. 26 /PRNewswire/ -- Easeamine® is the first over-the-counter, anti-aging cream that increases the production of collagen and elastin through its patented formula which delivers Adenosine to the lower layers of the skin. Adenosine, a natural compound found throughout the body, increases dermal fibroblast protein production, such as collagen and elastin, thus easing fine lines and wrinkles associated with aging. When delivered into the lower layers of...

2009-10-31 13:34:44

Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Priapism is a condition of persistent painful penile erection in the absence of sexual desire. It is highly associated with sickle cell disease, leukemia and other blood disorders. It can also result from vasoactive...

2009-10-02 12:00:00

MINNEAPOLIS, Oct. 2 /PRNewswire/ -- A new analysis reaffirms that Lexiscan® (regadenoson) Injection, the first selective A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress, requires infrequent use of the drug aminophylline to reverse its effect in the case of adverse events. The low use of aminophylline demonstrates that Lexiscan is...

2009-09-01 08:00:00

SCHAUMBURG, Ill., Sept. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of adenosine injection, USP, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia. Sagent will offer this latex-free, preservative-free adenosine product in 6 mg per 2 mL single-dose glass vials for intravenous use. "This launch expands upon the full line of prefilled adenosine syringes we introduced in 2007,...

2009-06-29 07:15:00

LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials. The protocol of these clinical trials has been approved by the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment process. ATPace(TM) is a novel, proprietary, stable, injectable formulation of adenosine...

2009-06-22 07:15:00

Technology Intended to Improve Outcome of Intrauterine Insemination and In Vitro Fertilization Procedures LA JOLLA, Calif., June 22 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has entered into an agreement with Clinical Trials International, LLC, (CTI), regarding a license to develop and market Cordex's drug candidate, ATPotent(TM). ATPotent(TM) is a novel ATP-based drug candidate designed for in vitro (outside of the human body)...